MedTrace Logo

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa

NCT04066036 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-10-23

No results posted yet for this study

Summary

This is a prospective observational cohort study enrolling participants in South Africa and Uganda who are prescribed an HIV treatment regimen containing lamivudine, tenofovir, and dolutegravir, which is known as TLD. We hope to better understand how effective TLD will be in sub-Saharan Africa. If treatment failure occurs, we seek to understand the possible reasons, including drug resistance and adherence challenges.

Conditions

Interventions

OTHER

This is an observational study only.

This is an observational study only.

Sponsors & Collaborators

  • Africa Health Research Institute

    collaborator OTHER

  • Mbarara University of Science and Technology

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Wellcome Trust

    collaborator OTHER

  • ViiV Healthcare

    collaborator INDUSTRY

  • Harvard Medical School (HMS and HSDM)

    collaborator OTHER

  • University of KwaZulu

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Suzanne M McCluskey, MD · Massachusetts General Hospital

  • Mark J Siedner, MD, MPH · Massachusetts General Hospital, Africa Health Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • South Africa
  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066036 on ClinicalTrials.gov